» Articles » PMID: 36102619

A Mouse Model of Lung Cancer Induced Via Intranasal Injection for Anticancer Drug Screening and Evaluation of Pathology

Overview
Journal FEBS Open Bio
Specialty Biology
Date 2022 Sep 14
PMID 36102619
Authors
Affiliations
Soon will be listed here.
Abstract

The pathologies and lethality of lung cancers are associated with smoking, lifestyle, and genomic factors. Several experimental mouse models of lung cancer, including those induced via intrapulmonary injection and intratracheal injection, have been reported for evaluating the pharmacological effect of drugs. However, these models are not sufficient for evaluating the efficacy of drugs during screening, as these direct injection models ignore the native processes of cancer progression in vivo, resulting in the inadequate pathological formation of lung cancer. In the present study, we developed a novel intranasal injection model of lung cancer simulating the native lung cancer pathology for anticancer drug screening. A mouse lung cancer cell line (Lewis lung carcinoma; LCC) was intranasally injected into mouse lungs, and injected cell number-dependent cancer proliferation was apparent in both the left and right lungs. Human non-small-cell lung cancer (NCI-H460) cells were also intranasally injected into nude mice and similarly showed injected cell number-dependent cancer growth. For the pharmacological evaluation of cisplatin, two different treatment frequencies were tested four times per month and twice a month. The intranasal injection model confirmed that cisplatin suppressed lung cancer progression to a greater extent under the more frequent treatment condition. In conclusion, these results indicated that our intranasal injection model is a powerful tool for investigating lung cancer pathology and may aid in the development of new anti-lung cancer agents.

Citing Articles

Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability.

Kaifi J, Joshi K, Suvilesh K, Natesh N, Manjunath Y, Coberly J Res Sq. 2025; .

PMID: 39975891 PMC: 11838710. DOI: 10.21203/rs.3.rs-5054204/v1.


In Vivo Bioluminescence Imaging of Tumor Progression in the Lewis Lung Carcinoma Orthotopic Mouse Model: A Comparison Between the Tail Vein Injection and Intranasal Instillation Methods.

Yamada-Hara M, Takahashi N, Byun J, Zeng L, Wang Z, Tanaka A Curr Protoc. 2024; 4(12):e70071.

PMID: 39660610 PMC: 11649249. DOI: 10.1002/cpz1.70071.


Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability.

Joshi K, Suvilesh K, Natesh N, Manjunath Y, Coberly J, Schlink S bioRxiv. 2024; .

PMID: 39569144 PMC: 11577786. DOI: 10.1101/2024.11.04.621940.


Non-invasive detection of orthotopic human lung tumors by microRNA expression profiling of mouse exhaled breath condensates and exhaled extracellular vesicles.

Mitchell M, Ben-Dov I, Liu C, Wang T, Hazan R, Bauer T Extracell Vesicles Circ Nucl Acids. 2024; 5(1):138-164.

PMID: 38863869 PMC: 11165456. DOI: 10.20517/evcna.2023.77.

References
1.
Li H, McSharry M, Bullock B, Nguyen T, Kwak J, Poczobutt J . The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res. 2017; 5(9):767-777. PMC: 5787226. DOI: 10.1158/2326-6066.CIR-16-0365. View

2.
McGee C, Sample C, Kilburg-Basnyat B, Gabor K, Fessler M, Gowdy K . Influenza-Mediated Lung Infection Models. Methods Mol Biol. 2019; 1960:191-205. PMC: 6675590. DOI: 10.1007/978-1-4939-9167-9_17. View

3.
Stankovic B, Bjorhovde H, Skarshaug R, Aamodt H, Frafjord A, Muller E . Immune Cell Composition in Human Non-small Cell Lung Cancer. Front Immunol. 2019; 9:3101. PMC: 6367276. DOI: 10.3389/fimmu.2018.03101. View

4.
Yamori T, Sato S, Chikazawa H, Kadota T . Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res. 1998; 88(12):1205-10. PMC: 5921337. DOI: 10.1111/j.1349-7006.1997.tb00350.x. View

5.
Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M . Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987; 47(22):5944-7. View